R
Roger Stupp
Researcher at Northwestern University
Publications - 463
Citations - 73077
Roger Stupp is an academic researcher from Northwestern University. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 93, co-authored 430 publications receiving 63025 citations. Previous affiliations of Roger Stupp include Merck & Co. & University of St. Gallen.
Papers
More filters
Journal ArticleDOI
PET Imaging in Glioma: The Neuro-Oncologist's Expectations
TL;DR: The limitations of the usual imaging techniques, and of the added value of PET-imaging in specific clinical situations are summarized and called for prospective studies and registries rather than the current largely resource-driven use of this valuable technique.
Journal ArticleDOI
31 Temozolomide (TMZ) targets only glioblastoma with a silenced MGMT-gene. Results of a translational companion study to EORTC 26981/NCIC CE.3 of radiotherapy ± TMZ
Monika E. Hegi,Annie-Claire Diserens,Marie-France Hamou,Thierry Gorlia,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Ulrich Bogdahn,G. Cairncross,Roger Stupp +9 more
A prospective, randomized, open label, phase iii clinical trial of novottf-100a vs best standard of care chemotherapy in patients with recurrent glioblastoma
Roger Stupp,Andrew A. Kanner,Herbert H. Engelhard,V. Heidecke,S. Taillibert,Frank S. Lieberman,V. Dbaly,Eilon D. Kirson,Yoram Palti,Philip H. Gutin +9 more
TL;DR: TTF as a single modality showed a higher response rate and longer time to treatment failure compared to best available chemotherapy, and overall survival also favored TTF, but did not reach statistical significance.
Journal ArticleDOI
The impact of the molecular classification of glioblastoma on the interpretation of therapeutic clinical trial results.
Lauren S. Singer,Alexander Z. Feldman,Robin Buerki,Craig Horbinski,Rimas V. Lukas,Roger Stupp +5 more
TL;DR: In this paper, the authors discuss updates on the molecular classification of glioblastoma (GBM) (and its histologic mimics) and provide suggestions for future clinical trial design with a focus on enrollment based upon molecular diagnostics.
Journal ArticleDOI
Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts
Matthew McCord,Elizabeth T. Bartom,Kirsten Bell Burdett,Aneta Baran,Frank Eckerdt,Irina V. Balyasnikova,Katy McCortney,Thomas K. Sears,Shi Yuan Cheng,Jann N. Sarkaria,Roger Stupp,Amy B. Heimberger,Atique U. Ahmed,C. David James,Craig Horbinski +14 more
TL;DR: In this article , the authors developed multiple treatment-resistant GBM models by exposing patient-derived xenografts (PDX) of GBM to radiation and temozolomide.